Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

Whether for drug screening or toxicity testing, stem cell-based 3D tissue models are key to biomedical research. However, producing cell aggregates in bioreactors is highly complex and cost-intensive.

Automated cell therapy manufacturing pioneer Cellares has hit a key milestone, gaining a current Good Manufacturing Practice (cGMP) stamp of approval for its Cell Shuttle factory-in-a-box, which is ...

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)--Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) and a leader in automated cell therapy manufacturing, and ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...

Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...